Chief Technology Officer, Phil Paik talks with GEN about how the company’s Fully Enzymatic Synthesis technology can overcome the length, purity, and accuracy limitations of the chemical DNA synthesis method.
Article Excerpt
“Customers are often limited by length, accuracy, and sequence complexity challenges,” says Phil Paik, PhD, CTO, Molecular Assemblies. “Our FES technology overcomes those limitations, enabling customers to unlock new research applications, such as in CRISPR therapeutics.”
